Viking Therapeutics Stock Surges on Acquisition Speculation

Shares of Viking Therapeutics experienced a dramatic surge yesterday, climbing an impressive 15.1% amid intensified takeover rumors and heightened retail trading activity. The stock price moved from $30.55 to $32.28 while trading volume reached 7.2 million shares, significantly exceeding average levels.

The substantial price movement appears driven by renewed speculation about Viking’s potential as an acquisition target. Market participants pointed to unconfirmed reports suggesting the obesity drug developer has become an attractive candidate for larger pharmaceutical companies seeking expansion. Viking’s established position within the lucrative GLP-1 weight-loss market represents a primary factor behind the acquisition interest.

Recent industry consolidation has further amplified these speculations. Pfizer’s acquisition of Metsera and Roche’s purchase of 89bio have demonstrated the growing appetite among... Read more...